LEARNING OBJECTIVES

Upon completion of this course, the learners should be able to:
• Apply strategies for early and accurate diagnosis of HCC stages
• Summarize mechanisms of action and clinical profiles of new and emerging immuno-oncology (IO) agents (mono and combo) for each stage of HCC
• Analyze data on IO therapy with liver-directed therapy procedures to identify appropriate patients
• Describe the role of HCC care team members and explain techniques to increase communication and collaboration

FACULTY 
Rony Avritscher, MD, FSIR
Department of Interventional Radiology
Professor of Interventional Radiology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ahmed Omar Kaseb, MD, CMQ
John E. and Dorothy J. Harris Professorship in Gastrointestinal Cancer Research
Member, National Hepatobiliary Task Force, NCI, USA
Tenured Professor and Director, Hepatocellular Carcinoma Program
Director, MD Anderson HCC SPORE
Editor-in-Chief, Journal of Hepatocellular Carcinoma 
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

PLANNING COMMITTEE
Adam Burgoyne, MD, PhD
Chair of the Steering Committee
Associate Clinical Professor
Department of Medicine
Division of Hematology/Oncology
University of California, San Diego
San Diego, California

Amit Singal, MD
Medical Director of the Liver Tumor Program
Clinical Chief of Hepatology
Professor of Internal Medicine
UT Southwestern Medical Center 
Dallas, Texas

Cindi Cantril, MPH, RN, OCN, CBCN
Cancer Resources Recovery
Geyersville, California

Isabel Newton, MD, PhD
Department of Radiology
Assistant Professor of Radiology
University of California, San Diego
San Diego, California

Rony Avritscher, MD, FSIR
Department of Interventional Radiology
Professor of Interventional Radiology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Sarah Manes, MS, CCLS
Liver Cancers Program Director
Global Liver Institute
Washington, DC

Stacey Stein, MD
Associate Professor of Internal Medicine
Assistant Medical Director, Clinical Trials Office
Yale Medicine
New Haven, Connecticut

Patrick Harty, PhD
Medical Director
The France Foundation

INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDIT
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the pre-test, completing the activity, and completing the post-test and evaluation form. A score of at least 75% on the post-test is required to successfully complete this activity. The participant may take the test until successfully passed.

Credit fulfillment
• If you are requesting AMA credits, ANCC credits, or a certificate of participation your certificate will be available for download 

Technical Requirements 
This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox, and Safari browsers.
Additionally, this site and its activities are best viewed using the latest operating system for your device.

ACCREDITED PROVIDER 

This activity is jointly provided by The France Foundation and Society for Interventional Oncology.
  

Accreditation Statement 

In support of improving patient care, this activity has been planned and implemented by The France Foundation and Society for Interventional Oncology. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES
The France Foundation designates this activity for 1.0 contact hours.

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and Society for Interventional Oncology (SIO) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and SIO resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and SIO seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and SIO are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Disclosure of Unlabeled Use:

TFF and SIO require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and SIO do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information. 

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an educational grant from AstraZeneca.

Disclaimer
The France Foundation and Society for Interventional Oncology present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, Society for Interventional Oncology, and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2023 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions: 
• The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered. 
• Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission 

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except when such information is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy. 

CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.